


Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

1. (cancelled)


2. (currently amended) ~~The compound of claim 1 wherein said compound~~
is a A compound of Formula III:



Formula III

and pharmaceutically acceptable prodrugs and salts thereof.

3. (currently amended) A method of treating diseases of ~~P450-expressing~~
tissues the liver in an animal ~~[[by]]~~ comprising administering a compound of Formula
III:



Formula III


and pharmaceutically acceptable prodrugs and salts thereof.

4. (currently amended) The method of claim 3 wherein said disease of ~~P450-expressing tissues~~ the liver is selected from the group consisting of cancers of the liver, ~~cancers of the colon~~, and viral infections of the liver.

5. (currently amended) The method of claim 4 wherein said disease of ~~P450-expressing tissues~~ the liver is hepatocellular carcinoma.

6. (cancelled)

7. (currently amended) A method of preventing recurrence of cancers in ~~P450-expressing tissues~~ the liver after medical or surgical treatment for said cancers in an animal ~~[[by]]~~ comprising administering a compound of Formula III:




Formula III

and pharmaceutically acceptable prodrugs and salts thereof.

8. (cancelled)

9. (original) The method of claim 7 wherein said animal is in remission from cancers and said administration of a compound of Formula III prevents further development of said cancers.

10. (currently amended) A method of increasing the therapeutic index of cytarabine for the treatment of a liver disease [[by]] comprising administering a compound of Formula III:




Formula III

and pharmaceutically acceptable prodrugs and salts thereof.

11. (cancelled)

12. (currently amended) ~~[[The]]~~ A pharmaceutical composition of claim 11

comprising a pharmaceutically effective amount of a compound of Formula III:




Formula III

and pharmaceutically acceptable prodrugs and salts thereof; and
pharmaceutically acceptable excipients.

13. (cancelled)

14. (currently amended) ~~[[The]]~~ A pharmaceutical composition of claim 13
comprising a pharmaceutically effective amount of Formula III:




Formula III

and pharmaceutically acceptable salts thereof, and a pharmaceutically effective amount of an oncolytic agent, or salts thereof, and pharmaceutically acceptable excipients.

15. (currently amended) The ~~method~~ pharmaceutical composition of claim 13 of claim 14 wherein said oncolytic agent is selected from ~~[[a]]~~ the group consisting of busulfan, carboplatin, cisplatin, miriplatin, temozolomide, thiotepa, melphalan, ifosfamide, cyclophosphamide, chlorambucil, doxorubicin, duanbrubicin, epirubicin, idarubicin, plicamycin, valrubicin, dactinomycin, gemcitabine, floxuridine, fluorouracil, mercaptopuine, thioguanine, methotrexate, mitomycin, etoposide, paclitaxel, docetaxel, irinotecan, topotecan, etoposide, teniposide, nedaplatin, carmustine, doxifluridine, cladribine, fludarabine, carmustine, mercaptopurine, thioguanine, azatoxin,

camptothecin, lurtotecan, camptothecin, 9-aminocamptothecin, pirarubin,
nrocarzinostatin, calicheamicin, esperamicin, and luroteca.

16. (currently amended) A method of treating cancers in ~~P450-expressing~~
~~tissues by~~ of the liver comprising administering a compound of Formula III:



Formula III

and pharmaceutically acceptable prodrugs and salts thereof;


and ~~[[by]]~~ comprising administering a pharmaceutically effective amount of an
oncolytic agent.

17. (original) The method of claim 16 wherein said oncolytic agent and said
compound of Formula III are administered separately.

18. (original) The method of claim 16 wherein said oncolytic agent and said
compound of Formula III are administered simultaneously.

19. (currently amended) The method of claim 16 wherein said oncolytic agent is selected from [[a]] the group consisting of busulfan, carboplatin, cisplatin, miriplatin, temozolomide, thiotepa, melphalan, ifosfamide, cyclophosphamide, chlorambucil, doxorubicin, duanorubicin, epirubicin, idarubicin, plicamycin, valrubicin, dactinomycin, gemcitabine, floxuridine, fluorouracil, mercaptopurine, thioguanine, methotrexate, mitomycin, etoposide, paclitaxel, docetaxel, irinotecan, topotecan, [[,]] etoposide, teniposide, nedaplatin, carmustine, doxifluridine, cladribine, fludarabine, carmustine, mercaptopurine, thioguanine, azatoxin, camptothecin, lurtotecan, camptothecin, 9-aminocamptothecin, pirarubin, nrocarzinostatin, calicheamicin, esperamicin, and luroteca.


20. (new) A compound of Formula III:



Formula III

or a pharmaceutically acceptable salt thereof.

21. (new) A method of treating diseases of the liver in an animal comprising administering a compound of Formula III:




Formula III

or a pharmaceutically acceptable salt thereof.

22. (new) The method of claim 21 wherein said disease of the liver is selected from the group consisting of cancers of the liver and viral infections of the liver.

23. (new) The method of claim 21 wherein said disease of the liver is hepatocellular carcinoma.

24. (new) A method of preventing recurrence of cancers in the liver after medical or surgical treatment for said cancers in an animal comprising administering a compound of Formula III:




Formula III

or a pharmaceutically acceptable salt thereof.

25. (new) The method of claim 24 wherein said animal is in remission from cancers and said administration of a compound of Formula III prevents further development of said cancers.


26. (new) A method of increasing the therapeutic index of cytarabine for the treatment of a liver disease comprising administering a compound of Formula III:



Formula III

or a pharmaceutically acceptable salt thereof.


27. (new) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula III:



Formula III

or a pharmaceutically acceptable salt thereof,
and pharmaceutically acceptable excipients.

28. (new) A pharmaceutical composition comprising a pharmaceutically effective amount of Formula III:




Formula III

or a pharmaceutically acceptable salt thereof,

and a pharmaceutically effective amount of an oncolytic agent, or salts thereof, and pharmaceutically acceptable excipients.

29. (new) The pharmaceutical composition of claim 28 wherein said oncolytic agent is selected from the group consisting of busulfan, carboplatin, cisplatin, miriplatin, temozolomide, thiotepa, melphalan, ifosfamide, cyclophosphamide, chlorambucil, doxorubicin, daunorubicin, epirubicin, idarubicin, plicamycin, valrubicin, dactinomycin, gemcitabine, floxuridine, fluorouracil, mercaptopurine, thioguanine, methotrexate, mitomycin, etoposide, paclitaxel, docetaxel, irinotecan, topotecan, etoposide, teniposide, nedaplatin, carmustine, doxifluridine, cladribine, fludarabine, carmustine, mercaptopurine, thioguanine, azatoxin, camptothecin, lurtotecan, camptothecin, 9-aminocamptothecin, pirarubin, nrocarzinostatin, calicheamicin, esperamicin, and luroteca.

30. (new) A method of treating cancers of the liver comprising administering a compound of Formula III:



Formula III

or a pharmaceutically acceptable salt thereof,
and comprising administering a pharmaceutically effective amount of an
oncolytic agent.

31. (new) The method of claim 30 wherein said oncolytic agent and said
compound of Formula III are administered separately.

32. (new) The method of claim 30 wherein said oncolytic agent and said
compound of Formula III are administered simultaneously.

33. (new) The method of claim 30 wherein said oncolytic agent is selected
from the group consisting of busulfan, carboplatin, cisplatin, miriplatin, temozolomide,
thiotepa, melphalan, ifosfamide, cyclophosphamide, chlorambucil, doxorubicin,
duanorubicin, epirubicin, idarubicin, plicamycin, valrubicin, dactinomycin, gemcitabine,
floxuridine, fluorouracil, mercaptopurine, thioguanine, methotrexate, mitomycin,
etoposide, paclitaxel, docetaxel, irinotecan, topotecan, etoposide, teniposide, nedaplatin,
carmustine, doxifluridine, cladribine, fludarabine, carmustine, mercaptopurine,
thioguanine, azatoxin, camptothecin, lurtotecan, camptothecin, 9-aminocamptothecin,
pirarubin, nrocarzinostatin, calicheamicin, esperamicin, and luroteca.